Novo Nordisk A/S announced on Monday that the European Commission recommended the use of its type 2 diabetes and anti-obesity medication Semaglutide, better known as Ozempic, for addressing the peripheral arterial disease (PAD) alongside the main issue it treats.
The decision came after the company's STRIDE PAD functional outcomes trial. Novo Nordisk said it expects the European Commission to update the medicine's label in about two months.
"Pending a decision from the European Commission, a STRIDE label update would complete the picture for Ozempic, making it the only GLP-1 RA to have proven risk reduction of cardiovascular death, heart attack, stroke, major kidney events and improvement in functional walking capacity in people with type 2 diabetes," the company's Product & Portfolio Strategy Executive Vice President Ludovic Helfgott said.
